The Health Committee says covering only about 6% of eligible people pushes over a million into private jabs, and it wants a crackdown on the black market.
Recap by typeshit. Full story at BBC.
TIKR points to retatrutide, due for filing in early 2027, and says a pending Seventh Circuit ruling on whether it counts as a biologic could decide 5 vs 12 years of exclusivity.
She lost 7 kilos in her first month, regained it during a month-long break, and now says she's eating more and gaining in week two back.
A shared report on doctors turning to GLP-1 medications for weight loss in some kids. Details are thin, so tap through for the full story.
The author, who holds Novo shares, cites Morgan Stanley's $190 billion obesity market forecast for 2035 and an NIH-funded mouse study on aging.
STAT
STAT reports that some addiction telehealth platforms now market branded and compounded GLP-1s for alcohol use disorder. Experts warn of fragmented care.
Mounting research points to possible effects on mood, reward, memory, fertility and neurodegenerative disease, though much of it is still early.
Loading…